12:45 PM
 | 
Feb 16, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA approves AMAG's new Makena formulation

FDA approved an sNDA from AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) for subcutaneous Makena hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women who spontaneously delivered one preterm baby in the past.

AMAG plans to launch subcutaneous Makena in the second half of...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >